mp.weixin.qq.com· 丁香园 Insight 数据库·· 6 hours agoPickScore67
FDA Approves Roche's Enspryng for Adults with Thyroid Eye Disease
首个且唯一！罗氏眼科新药新适应症获批上市
In brief
The FDA has approved Roche's Enspryng (satralizumab), an IL-6 receptor antibody, to treat adults with thyroid eye disease (TED), Roche announced on October 16. It is described as the first and only at-home subcutaneous injection treatment for these patients. The drug was first approved by the FDA in August 2020 for neuromyelitis optica spectrum disorder (NMOSD) in adults, and TED is its second approved indication.
Why it matters
FDA approval of a second indication for an existing Roche biologic affects treatment options in thyroid eye disease.
Source: mp.weixin.qq.com · mp.weixin.qq.com